CN104936464A - 包含产丙酸活细菌的婴儿食物组合物 - Google Patents
包含产丙酸活细菌的婴儿食物组合物 Download PDFInfo
- Publication number
- CN104936464A CN104936464A CN201480005065.3A CN201480005065A CN104936464A CN 104936464 A CN104936464 A CN 104936464A CN 201480005065 A CN201480005065 A CN 201480005065A CN 104936464 A CN104936464 A CN 104936464A
- Authority
- CN
- China
- Prior art keywords
- food composition
- composition
- bacterium
- lactic acid
- sibling species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 118
- 241000894006 Bacteria Species 0.000 title claims abstract description 83
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title claims description 62
- 235000019260 propionic acid Nutrition 0.000 title claims description 31
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 title claims description 31
- 235000008452 baby food Nutrition 0.000 title abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 74
- 239000004310 lactic acid Substances 0.000 claims abstract description 37
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 37
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 21
- 208000002881 Colic Diseases 0.000 claims abstract description 13
- 206010021746 Infantile colic Diseases 0.000 claims abstract description 13
- 230000035945 sensitivity Effects 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims description 35
- 235000013350 formula milk Nutrition 0.000 claims description 26
- 241000894007 species Species 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 241000186429 Propionibacterium Species 0.000 claims description 12
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 10
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims description 10
- 235000013406 prebiotics Nutrition 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 241001478240 Coccus Species 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 6
- 210000001835 viscera Anatomy 0.000 claims description 6
- 235000021125 infant nutrition Nutrition 0.000 claims description 5
- 241000186425 Acidipropionibacterium jensenii Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- -1 hexamethylene resin acid Chemical compound 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 3
- 241000186426 Acidipropionibacterium acidipropionici Species 0.000 claims description 2
- 241000248408 Acidipropionibacterium microaerophilum Species 0.000 claims description 2
- 241000186335 Acidipropionibacterium thoenii Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- 241000604449 Megasphaera Species 0.000 claims description 2
- 241000908493 Propionibacterium cyclohexanicum Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000605036 Selenomonas Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 2
- 206010017999 Gastrointestinal pain Diseases 0.000 abstract 1
- 229960000448 lactic acid Drugs 0.000 abstract 1
- 230000009278 visceral effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 210000000936 intestine Anatomy 0.000 description 13
- 239000000843 powder Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 241001531197 [Eubacterium] hallii Species 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 102000015781 Dietary Proteins Human genes 0.000 description 7
- 108010010256 Dietary Proteins Proteins 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 235000021245 dietary protein Nutrition 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229940009289 bifidobacterium lactis Drugs 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000012041 food component Nutrition 0.000 description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 210000004251 human milk Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000005428 food component Substances 0.000 description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241001156739 Actinobacteria <phylum> Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000360590 Erythrites Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010049976 Impatience Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000604448 Megasphaera elsdenii Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001148135 Veillonella parvula Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229950010118 cellacefate Drugs 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/61—Propionibacterium
- A23V2400/617—Freudenreichii
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pediatric Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及包含利用乳酸产丙酸型活细菌以及产乳酸活细菌的组合物,特别是婴儿食物组合物,其生产和在治疗消化系统疾病中的用途,特别是在治疗婴儿腹痛、肠道不适、肠痛、内脏敏感和肠痉挛中的用途。
Description
本发明涉及包含产丙酸活细菌的组合物,特别是婴儿食物组合物,其生产和在治疗消化系统疾病,特别是治疗婴儿腹痛(IC)中的用途。
已知来自健康和营养良好的母亲的人乳在生命的前几个月期间为婴儿提供充足的营养并且也显著降低在这段关键的发育时期期间的急性和慢性疾病的风险。对于婴儿营养产品,人乳的化学组成用作婴儿制剂配制的指南。近年来,选定的生理后果已经在证明新成份功能中被接受,这些成份包括一些未在人乳中发现的化学实体。
Callaghan等(婴儿配方,收录于《乳制品科学百科全书》(Encyclopedia ofDairy Sciences)(第二版),编者:John W.Fuquay,Elsevier Ltd,第135-145页,通过引用纳入)总结了监管婴儿营养产品的生产、组成和标记的规定。这些规定确保了产品的安全性和功效,但是也对新的营养产品造成限制。
包括益生菌剂在内的多种婴儿营养产品已市售可得。这些产品包含选定的乳酸生产物(双歧杆菌或乳杆菌):补充了乳双歧杆菌(Bifidobacterium lactis)的雀巢(Nestle)补充了路氏乳杆菌(Lactobacillus reuteri)的 补充了路氏乳杆菌的
此外,多篇文献涉及包含细菌并具有治疗用途的营养产品。
WO2004/085628描述了乳酸利用细菌及其治疗用途,尤其是用于治疗炎性疾病。
WO011/020780描述了包含乳杆菌菌株的营养组合物及其治疗用途,尤其是用于治疗过敏症状。
US2010/0166721描述了益生菌组合物并泛泛描述其用作食物补充剂用于中和肠胃菌群。
EP1374878描述了用于预防或缓解胃肠道吸收不良症状的方法和组合物。
US2004/0062758描述了益生菌的组合及其在刺激免疫系统和总体健康改善中的用途。
WO2012/059502描述了包含益生菌微生物的基于谷物的粉末组合物及其在增强免疫系统或治疗炎性疾病中的用途。该文献专门涉及非复制型微生物。
US2012/0171166描述了特定寡糖的共生组合以促进有益微生物群的生长及其在治疗胃肠疾病中的用途。该文献专门涉及产丙酮酸细菌。
US2007/0258953描述了包含新的乳酸利用型活细菌的益生菌组合物;及其作为药物的用途。
US2005/0180963描述了包含新型活丙酸杆菌的益生菌组合物,及其在治疗胃肠疾病中的用途。
上述文献都没有解决治疗选自下组的消化系统疾病或病症:腹痛、肠道不适、肠痛、内脏敏感和肠痉挛,尤其是治疗婴儿腹痛。甚至在今天,据信仍没有已知的婴儿腹痛的公认治疗。因此,存在未满足的临床需求。
因此,本发明的目的是解决这一临床需求并克服现有技术的这些不足中的至少一些。具体地,本发明的目的是提供用于治疗消化系统疾病,如IC的食物/药物组合物以及用于治疗上述疾病的方法。
通过权利要求1中定义的组合物实现了这些目的。在说明书和独立权利要求中公开了本发明的其他方面,在说明书和从属权利要求中公开了优选的实施方式。
下面将更详细地描述本发明。应理解,本文提供/揭示的各种实施方式、优选和范围可随意组合。此外,根据具体实施方式,特定的限定、实施方式或范围可能不适用。
除非另外说明,应在本说明书中应用以下的定义:
如本文所用,描述本发明的内容时使用的术语“一个”、“一种”、“该”等类似表达(尤其在权利要求书的内容中)应解释为涵盖单数和复数,除非另有说明或者清楚地否认。
本文所用术语“包含”、“含有”和“包括”以其开放、非限定的含义使用。
术语“治疗”也应包括进展的延迟以及防止(预防)。
术语“消化系统疾病”和“消化系统病症”是熟知的并且描述了关于胃肠道,尤其是肠的疾病/病症。具体包括的有婴儿腹痛(“IC”)。在从出生到4个月的婴儿中,IC的诊断标准必须包括所有的以下内容:1.阵发没有明显原因而开始或停止的易怒、焦躁或啼哭2.至少1周中至少每周3天发生每天持续3小时或更久的发作3.没有发育停滞。IC也称为小儿腹痛,ICD-10:R10.4。
术语“产丙酸细菌”是产生丙酸盐作为碳代谢主要产物的一组细菌。
与“丙酸杆菌”同义的术语“丙酸细菌”是本领域中熟知并确立的;它们根据其产生丙酸作为主要代谢终产物的独特代谢而命名。这种细菌可发酵大量的底物,包括乳酸盐。丙酸发酵的主要终产物是丙酸、乙酸和琥珀酸以及CO2。糖底物(主要是葡萄糖)首先通过糖酵解或通过戊糖磷酸途径被氧化成丙酮酸,产生ATP和还原的辅酶。丙酮酸进一步通过两种主要的途径异化,产生丙酸或乙酸和CO2。乳酸可通过丙烯酸途径代谢成丙酸,其中从乳酸中去除水形成丙烯酸,其随后还原成丙酸(《微生物生理学》(Microbial Physiology).Albert G.Moat,John W.Foster和Michael P.Spector,Wiley-Liss,Inc.)。
丙酸细菌在美国是公认安全使用物质(GRAS)并且在欧洲有安全资格认证(QPS)。
丙酸细菌与其他GC含量超过50%的革兰氏阳性菌一起分类为放线细菌(Actinobacteria)。
术语“利用乳酸产丙酸型细菌”和“产乳酸细菌”如下文定义。
术语“益生菌剂”是本领域中熟知并确立的,并且具体涉及对人类的健康有有益效果的微生物细胞组分或微生物细胞制品。因此,术语益生菌剂包括上述定义的细菌。
术语“益生元”是本领域熟知并确立的并且具体涉及下述不可消化的食物成份,其通过选择性刺激结肠中一种或有限数量的细菌的生长和/或活性有益地影响人类,并由此改善人类健康。
更概括来说,在第一方面,本发明涉及包含产丙酸活细菌,优选利用乳酸产丙酸型活细菌的新组合物。这些本发明的组合物可适用于食物组合物,尤其是婴儿食物组合物和/或药物组合物。在下文中更详细地解释本发明的这一方面:
食物组合物:本发明的组合物可以是任意形式的食物组合物。优选地,该组合物适用于幼儿营养物,尤其是婴儿营养物。因此,该食物组合物可以是婴儿1段配方、后续配方、婴儿食物配方、婴儿谷物配方或成长奶(growing-upmilk)。这类食物组合物是已知的并且描述于,例如Callaghan等(婴儿配方,收录于《乳制品科学百科全书》(第二版),编者:John W.Fuquay,Elsevier Ltd,第135-145页,通过引用纳入)。通常,如下所述,这类食物组合物包含添加剂和生长增强元素。术语食物组合物也涵盖供需要治疗的个体的成人营养组合物或成人乳-蛋白基饮料。优选地,所述食物组合物是1段婴儿配方,如婴儿奶或婴儿奶粉。
药物组合物:本发明的组合物可以是任意形式的药物制剂,如固体、半固体或液体制剂。此外,上述食物组合物还可以用作药物组合物。在待给药的组合物以外,药物组合物也包含给药说明书(“包装插页”)。
活(活体)细菌:使用活(活体)细菌被认为是本发明区别于现有技术并能够进行本文所述的用途的关键特征。根据本发明,细菌是活的(活体),即它们是有代谢活性和/或能够移生于哺乳动物肠部,尤其是人的肠。该术语包含(i)能够分裂并形成菌落的细菌以及(ii)非复制型细菌。组(i)的细菌能够在适于细菌生长的营养介质上分裂并形成菌落,或者在用不同浓度的细菌制剂接种并在合适的条件(持续至少24小时的好氧和/或厌氧环境)下孵育之后能增加液体生长介质的浊度。这些经典接种方法是已知的并见述于,例如Jay等(《现代食物微生物学》(Modern Food Microbiology),第7版,Springer,2005)。组(ii)的细菌包括活的但是非复制型的细菌,其可以用靶向细菌膜电势或酶活性的荧光染剂计数,这些能区分活性、代谢活性、受损的、休眠的、活的但不可培养的,与死的细菌细胞。分子工具如荧光原位杂交(FISH)和流式细胞术已成功用于评估益生菌产品中的活性细胞。
在一个优选的实施方式中,本发明涉及包含组(i)的细菌的组合物。
在另一个实施方式中,本发明涉及还包含组(ii)的细菌的组合物。
在另一个实施方式中,本发明涉及仅包含组(ii)的细菌的组合物。
这种细菌的量可在宽的范围内变化并且可由本领域技术人员在常规实验中确定有效量。对于该目的有效的量将取决于本领域技术人员已知的多个因素,如待治疗的人的体重和总体健康状况,以及食物基础的影响。通常,本发明的组合物中的有效量的范围是每g或每mL组合物102至1012cfu,更优选104至109cfu,最优选107至109cfu。
利用乳酸产丙酸型细菌:在一个优选的实施方式中,产丙酸细菌选自“利用乳酸产丙酸型细菌”。使用乳酸通过丙烯酸途径来产生丙酸的肠细菌包括丙酸杆菌及其近缘种、韦荣氏球菌及其近缘种、月形单胞菌及其近缘种、巨球形菌及其近缘种、以及任意其他分离自婴儿肠生态系统中的利用乳酸产丙酸型细菌。丙烯酸途径已知并见述于文献中,例如,Hosseini等(Nutr.Rev.9:245-258,2011),具体是图2,其通过引用全文纳入本文。
在另一个优选的实施方式中,产丙酸细菌选自目前已知的13个种。
在另一个优选的实施方式中,产丙酸细菌选自费氏丙酸杆菌(P.freudenreichii)、产丙酸丙酸杆菌(P.acidipropionici)、詹氏丙酸杆菌(P.jensenii)、特氏丙酸杆菌(P.thoenii)、环己脂酸丙酸杆菌(P.cyclohexanicum)和微需氧丙酸杆菌(P.microaerophilum)。
因此,本发明提供了一种组合物,具体是一种食物组合物或药物组合物,包含(i)来自一种或多种活细菌菌株的产丙酸活细菌,特别是来自本文指出的菌株;(ii)可选的蛋白来源,(iii)可选的碳水化合物来源,(iv)可选的脂质来源;(v)可选的维生素和矿物质来源;(vi)可选的添加剂;(vii)可选的水。
本发明的组合物通常含蛋白来源。合适的量不超过2.0g/100kcal,优选1.8至2.0g/100kcal。据信蛋白的类型对本发明并不重要,条件是满足必需氨基酸含量的最低要求并且确保令人满意的生长,尽管优选超过50重量%的蛋白来源是乳清。因此,可以使用基于乳清、酪蛋白及其混合物的蛋白来源以及基于大豆的蛋白来源。对乳清蛋白而言,蛋白来源可以基于酸乳清或甜乳清或其混合物,并且可以所需的任意比例包含α-乳清蛋白和β-乳球蛋白。
本发明的组合物通常含碳水化合物来源。虽然优选的碳水化合物来源是乳糖,但是可以使用通常在婴儿配方中发现的任意碳水化合物来源,如乳糖、蔗糖、麦芽糊精、淀粉及其混合物。优选地,碳水化合物来源贡献组合物总能量的35%至65%。
本发明的组合物通常含脂质来源。脂质来源可以是适用于婴儿配方的任意脂质或脂肪。优选的脂肪来源包括棕榈油、高油酸葵花油和高油红花油。也可加入必需脂肪酸亚油酸和α-亚麻酸,同样可加入少量含大量预制的花生四烯酸和二十二碳六烯酸的油如鱼油或微生物油。总之,脂肪含量优选贡献配方总能量的30%至55%。脂肪来源优选具有约5:1至约15:1,例如约8:1至约10:1的n-6脂肪酸与n-3脂肪酸之比。
本发明的组合物通常含理解为对于日常膳食必要且在营养上显著量的所有维生素和矿物质。已经确立了某些维生素和矿物质的最低要求。婴儿配方中可选存在的矿物质、维生素和其他营养的示例包括维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素E、维生素K、维生素C、维生素D、叶酸、肌醇、烟酸、生物素、泛酸、胆碱、钙、磷、碘、铁、镁、铜、锌、锰、氯、钾、钠、硒、铬、钼、牛磺酸和L-肉毒碱。矿物质通常以盐的形式加入。具体矿物质和其他维生素的存在和量会根据预期的婴儿群体而变化。
本发明的组合物是干的。这确保了包含本文定义的活细菌的稳定组合物。然而,低水含量(通常低于5%)可能可以接受并且因此包含于本发明中。
本发明的组合物还可含其他组分,其可具有有益的效果,如纤维、乳铁蛋白、核苷酸、核苷等。
本发明的组合物还可含有乳化剂和稳定剂,如大豆卵磷脂、柠檬酸的单甘油酯和双甘油酯等。如果该组合物以液体形式提供,尤其如此。
本发明的组合物还可含有稳定剂(或“稳定化试剂”)。该术语指加入组合物中以增加湿制剂的粘度或形成水凝胶的化合物或材料。合适的稳定剂的示例包括,但不限于多糖,如乙酸邻苯二甲酸纤维素(CAP)、羧甲基纤维素、果胶、藻酸钠、藻酸的盐、羟丙基甲基纤维素(HPMC)、甲基纤维素、角叉菜胶、瓜耳胶、阿拉伯树胶、黄原胶、刺槐豆胶、壳聚糖和壳聚糖衍生物、胶原、聚乙醇酸、淀粉和改性淀粉、环糊精和寡糖(菊糖、麦芽糊精、棉子糖、葡聚糖等)及其组合。
本发明的组合物还可含有保护试剂(或“保护性试剂”或“保护剂”)。该术语指为确保或增加活细菌在干燥工艺期间和之后的稳定性,或为了干粉产品的长期储存稳定性而添加的化合物或材料。合适的保护剂通常易溶于溶液并且不在与水接触后变厚或聚合。合适的保护剂如下所述,并且包括但不限于:蛋白质如人和牛血清白蛋白、乳清蛋白、大豆蛋白、酪蛋白酸盐、明胶、免疫球蛋白、碳水化合物包括单糖(半乳糖、D-甘露糖、山梨糖等)、二糖(乳糖、海藻糖、蔗糖等);氨基酸如谷氨酸单钠、赖氨酸、甘氨酸、丙氨酸、精氨酸或组氨酸以及疏水性氨基酸(色氨酸、酪氨酸、亮氨酸、苯丙氨酸等);甲胺如甜菜碱;赋形剂盐如硫酸镁;多元醇如三元或更多元糖醇(如甘油、赤藓醇、甘油、阿拉伯糖醇、木糖醇、山梨糖醇和甘露醇);丙二醇;聚乙二醇;普罗流尼;表面活性剂;及其组合。
本发明的组合物还可含益生元添加剂。该术语指用于刺激特定肠微生物,如本文定义的活细菌的生长的化合物/材料。合适的益生元是本领域技术人员已知的并且是不可消化的食物成份,其通过选择性刺激结肠中一种或有限数量细菌的生长和/或活性来对宿主产生有益的影响。这些成份从它们在胃或小肠中不被降解和吸收并因此完整地通向结肠而在结肠被有益细菌选择性发酵的意义上说是不可消化的。合适的益生元的示例包括某些寡糖,如果低聚果糖(FOS)、阿拉伯胶和低聚半乳糖(GOS)。可以使用益生元的组合,如短链GOS和长链FOS,如以商标销售的产品(Arslanoglu S等,J Nutr 2008;138:1091-5)。
在一个优选的实施方式中,本发明提供的组合物包含本文定义的活细菌和本文定义的益生元的组合。如本文所示,两种组分的组合显著改善了治疗和/或预防效果(协同效应)。
在另一个优选的实施方式中,本发明提供的组合物包含本文定义的活细菌和产乳酸细菌的组合。优选地,产乳酸细菌选自乳酸菌和双歧杆菌。优选地,产乳酸细菌选自以下菌株:双歧杆菌、乳杆菌、乳球菌、链球菌、肠球菌、明串珠菌、魏斯氏菌。如本文所述,发现产乳酸细菌和乳酸利用细菌的组合特别有益于食物组合物。同时,如本文所述,这些产乳酸细菌是活的。
本发明的组合物可以易于给予的液体组合物(即,“婴儿配方”、“婴儿奶”)或使用前用水重建的干组合物(即,“婴儿奶粉”、“补充剂”)提供。为了在储存直至耗用期间保持含益生菌产品的活性,益生菌可仅以干燥形式和配方制品(液体或粉末)一同提供。
在液体组合物的情况中,以干燥形式(“补充剂”)与产品分开提供活性细菌,其可在使用前添加。在该实施方式中,本发明提供了多部分试剂盒,第一部分是包含活细菌的固体剂型而第二部分是不含活细菌的液体产品(如婴儿奶)。
在干组合物(如奶粉)的情况中,含活细菌的干婴儿配方组合物优选具有低于0.2,优选低于0.15的水活度,以进一步增加储存稳定性。低水活度降低了粉末的分解速度并阻止微生物的生长或活性。一般使用对应于大约5%,优选2.5%至3.5%的低于0.2或更低的水活度值来阻止乳糖结晶,并且显著降低奶粉中化学和酶促反应的速度。
在第二方面,本发明涉及本发明的组合物作为药物,尤其是用于治疗消化系统疾病的用途。本文所述的组合物提供了能够在人特别是婴儿中促进或重新建立健康肠菌群的有用的细菌聚生体。在下文中更详细地解释本发明的这一方面。
本发明的组合物具有治疗和/或预防效果,并且可特别用于在有此需求的患者或婴儿中治疗消化系统疾病,或用于在有此需求的患者或婴儿中降低消化系统疾病的风险,或用于降低在有此需求的患者或婴儿中消化系统疾病的严重性。
因此,本发明也提供了如本文所述的组合物用作药物。
本发明还提供
■本文所述的组合物在制备用于治疗消化系统疾病或病症的药物中的用途;
■本文所述的组合物的治疗用途;
■一种治疗消化系统疾病或病症的方法,该方法包括向有此需求的对象给予有效量的本文所述的组合物的步骤;
■用于治疗消化系统疾病或病症的本文所述的组合物;
■供消化系统疾病或病症的治疗中使用的本文所述的组合物。
本发明的组合物包含的本文定义的活细菌的量足以至少部分促进健康益处。实现此目的的量被定义为“治疗有效剂量”。对于该目的有效的量将取决于本领域技术人员已知的多个因素,如待治疗的人的体重和总体健康状况,以及食物基础的影响。在预防性应用中,向病症易感或另行有患病风险的消费者给予一定量的本发明的组合物,该量足以至少部分降低发生本文定义的病症的风险。这种量被定义为“预防有效剂量”。对于该目的有效的量将取决于本领域技术人员已知的多个因素,如待处理的人的体重和总体健康状况,以及食物基础的影响。
不受理论限制,认为本发明背后的科学合理性可总结如下:
(1)婴儿肠微生物群含有大且高度多样性的产乳酸细菌(主要是双歧杆菌、乳杆菌、链球菌和葡萄球菌)。塑造乳酸利用共同体(LUB)的很多其它物种在早期也定居于婴儿的肠,包括硫酸还原菌(SRB)和非SRB(=LUB)。在婴儿中,LUB菌群主要是霍氏真杆菌(E.hallii)和韦荣氏球菌。因此,在胃肠道中存在有霍氏真杆菌(E.hallii)、韦荣氏球菌和SRB参与的对乳酸的强烈竞争。SRB和霍氏真杆菌(E.hallii)与韦荣氏球菌一起在生命的前3个月在婴儿肠微生物群中占主导,其群在第4个月时会进一步增加。
(2)高LUB群由叫喊(screaming)发现并分组。在这些婴儿中LUB受到促进并且可能存在对乳酸盐的巨大竞争。叫喊可能是这种胃肠道中的细菌竞争通过促进某些微生物的生长或有害细菌代谢物的产生造成的结果。
(3)因此,利用乳酸产丙酸型细菌可能在早期主导该共同体,影响该细菌共同体的整体平衡。目的将是降低SRB和霍氏真杆菌群或产生的代谢物。事实上,SRB产生H2S而霍氏真杆菌产生大量H2,两者都与人的疼痛和肠道不适相关。
(4)利用乳酸产丙酸型细菌可将肠道乳酸转化成丙酸并将其从肠生态系统中除去。这种方法防止了任何乳酸积累,但也影响产生婴儿叫喊和腹痛潜在关联的负面化合物的其他乳酸利用细菌的生长和代谢。
发明人现在认识到利用乳酸产丙酸型细菌可通过在生命的前几个月产生更健康和平衡的营养链在疝气痛的婴儿中减少H2S和H2的产生。在优选的实施方式中,消化系统病症因此是婴儿腹痛(也称为“IC”或“小儿腹痛”或“幼儿腹痛”)。
在另一个优选的实施方式中,消化系统疾病或病症选自下组:腹痛、肠道不适、肠痛、内脏敏感和肠痉挛。
在另一个优选的实施方式中,消化系统疾病是腹痛。
在另一个实施方式中,本发明的组合物用来防止患者(尤其是婴儿)肠中的乳酸积累。这种功能障碍被认为会另外导致酸中毒和/或腹痛。
在另一个实施方式中,本发明的组合物用来减少患者(尤其是婴儿)肠中的H2S产生。这种用途被认为能预防腹痛和/或结肠炎。
在其他实施方式中,本发明的组合物用来模拟在母乳中观察到的营养链。这被认为向新生儿提供了最佳营养。
在另一个实施方式中,本发明的组合物用来控制肠菌群和肠道生态或使之正常化。这被认为改善了肠道健康。
如上述,具体的相关患者组是新生婴儿。发现剖腹产的婴儿是特别重要的待治疗患者组。然而,本发明并不限于这一特定患者组,本发明也可用于治疗(i)新生婴儿(一般不到1个月),(ii)婴儿(一般不到12个月)和(iii)小儿(一般不到36个月)。
在第三方面,本发明涉及一种用于制造如本文所述的组合物的方法。在下文中更详细地解释本发明的这一方面:
包括活(活体)细菌菌株的原料是已知的或可通过已知方法得到。本发明的组合物的生产主要取决于最终产物的类型:干产品,即固体形式(如粉末)或湿产品,即液体(如饮料)或半液体(如泥)。
通常,可以使用已知用于生产包含活(活体)细菌的食物产品的所有方法。通常,生产食物产品并且加入活菌制剂。
通常,活细菌可以按照任意合适的方法培养并通过例如冻干或喷雾干燥制备以供添加至本发明的组合物中。在Lacroix等(《食物成份、酶和营养剂的微生物生产》(Microbial production of food ingredients,enzymes and nutraceuticals),McNeil,Giavasis,Harvey编,Woodhead出版公司,Cambridge,(2012))中可发现详细内容,其通过引用纳入。或者,细菌制品可从专业人员处以已经制备成适于加入本发明的组合物的形式得到。
在优选的实施方式中,本发明的组合物是奶粉。奶粉生产是已确立的技术并且在例如Walstra(《乳制品科学和技术》(Dairy science and technology),第2版,Boca Raton:Taylor&Francis,782pp.(2006))和Schuck(奶粉:类型和生产,收录于《乳制品科学百科全书》(第二版)(Encyclopedia of Dairy Sciences),学术出版社(Academic Press),第108–116页(2011))中描述,两者通过引用纳入。
例如,可通过将蛋白来源、碳水化合物来源和脂肪来源以合适的比例掺混在一起来制备本发明的组合物。如果使用,掺混物中可包含乳化剂。维生素和矿物质可在这个时间点加入,但是通常在之后加入以避免热降解。任何亲脂性维生素、乳化剂等可在掺混之前溶于脂肪来源。然后其中可混入水,优选已经过反渗透处理的水以形成液体混合物。
然后液体混合物可经过热处理以降低细菌载量。例如,可将液体混合物快速加热到约80℃至约110℃范围的温度,持续约5秒至约5分钟。这可通过流注射或通过热交换器进行;例如板式热交换器。
然后可通过例如闪蒸冷却将液体混合物冷却至约60℃至约85℃。然后可使得液体混合物均质化,例如在两个阶段中均质化,在第一阶段约7MPa至约40MPa而在第二阶段约2MPa至约14MPa。然后可进一步冷却均质化的混合物以添加任意热敏组分;如维生素和矿物质。在这一时间点,均质化混合物的pH和固体含量被方便地标准化。将均质化混合物转移至合适的干燥设备,如喷雾干燥器或冷冻干燥器并转化成粉末。粉末的水分含量应低于约5重量%。
为了进一步说明本发明,给出以下实施例。提供这些实施例并不旨在限制本发明的范围。
下文给出了本发明的用于婴儿或小儿的一组按年龄调整的营养组合物。
以下是所含细菌的说明:
(1)费氏丙酸杆菌(P.freudenreichii);(2)费氏丙酸杆菌(P.freudenreichii)和乳双歧杆菌BB12(Bifidobacterium lactis BB12);(3)费氏丙酸杆菌(P.freudenreichii)和鼠李糖乳杆菌GG(Lactobacillus rhamonosus GG);(4)埃氏巨球形菌(Megasphera elsdensii)
(5)小韦荣氏球菌(Veillonella parvula);(6)可选的GOS。
Claims (14)
1.一种干的食物组合物,其包含:
(a)来自一种或多种活细菌菌株的产乳酸活细菌;
(b)来自一种或多种活细菌菌株的利用乳酸产丙酸型活细菌;和
(c)可选的益生元;
用于治疗选自下组的消化系统疾病或病症:腹痛、肠道不适、肠痛、内脏敏感和肠痉挛。
2.如权利要求1所述的食物组合物,用于治疗婴儿腹痛。
3.如权利要求1或2所述的食物组合物,其特征在于,所述利用乳酸产丙酸型活细菌(b)选自下组:丙酸杆菌及其近缘种、韦荣氏球菌及其近缘种、月形单胞菌及其近缘种、巨球形菌及其近缘种。
4.如权利要求3所述的食物组合物,其特征在于,所述利用乳酸产丙酸型活细菌(b)选自以下菌株:费氏丙酸杆菌(P.freudenreichii)、产丙酸丙酸杆菌(P.acidipropionici)、詹氏丙酸杆菌(P.jensenii)、特氏丙酸杆菌(P.thoenii)、环己脂酸丙酸杆菌(P.cyclohexanicum)和微需氧丙酸杆菌(P.microaerophilum)。
5.如前述权利要求中任一项所述的食物组合物,其特征在于,所述产乳酸活细菌(a)选自乳酸菌和双歧杆菌。
6.如权利要求5所述的食物组合物,其特征在于,所述产乳酸活细菌(a)选自:双歧杆菌及其近缘种、乳杆菌及其近缘种、乳球菌及其近缘种、链球菌及其近缘种、肠球菌及其近缘种、明串珠菌及其近缘种、魏斯氏菌及其近缘种。
7.如前述权利要求中任一项所述的食物组合物,所述组合物还包含添加剂和/或生长增强补充剂和/或益生元。
8.如前述权利要求中任一项所述的食物组合物,其特征在于,所述益生元选自FOS和GOS。
9.如前述权利要求中任一项所述的食物组合物,其特征在于,所述活细菌的量在每克或每mL组合物中102至1012CFU范围内。
10.如前述权利要求中任一项所述的食物组合物,所述食物组合物是婴儿营养产品,优选婴儿奶或婴儿奶粉。
11.如前述权利要求中任一项所述的食物组合物,(i)所述食物组合物设计为从6个月大开始给予小儿或婴儿,并且(ii)提向小儿或婴儿提供完全的营养。
12.一种婴儿配方,包含如权利要求1-9中任一项所述的干的食物组合物,用于治疗选自下组的消化系统疾病或病症:腹痛、肠道不适、肠痛、内脏敏感和肠痉挛。
13.如权利要求12所述的婴儿配方呈婴儿奶形式,用于治疗选自下组的消化系统疾病或病症:腹痛、肠道不适、肠痛、内脏敏感和肠痉挛。
14.如权利要求12所述的婴儿配方呈多部分试剂盒形式,其中,第一部分包含如权利要求1-9中任一项所述的干的食物组合物并且第二部分包含不含产丙酸活细菌的婴儿配方,特别是婴儿奶,用于治疗选自下组的消化系统疾病或病症:腹痛、肠道不适、肠痛、内脏敏感和肠痉挛。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13000283.5 | 2013-01-21 | ||
EP13000283 | 2013-01-21 | ||
PCT/CH2014/000006 WO2014110685A1 (en) | 2013-01-21 | 2014-01-14 | Baby food composition comprising viable propionic acid-producing bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104936464A true CN104936464A (zh) | 2015-09-23 |
Family
ID=47598664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480005065.3A Pending CN104936464A (zh) | 2013-01-21 | 2014-01-14 | 包含产丙酸活细菌的婴儿食物组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150352162A1 (zh) |
EP (1) | EP2945494B1 (zh) |
JP (1) | JP2016505024A (zh) |
CN (1) | CN104936464A (zh) |
CA (1) | CA2897363C (zh) |
ES (1) | ES2620057T3 (zh) |
WO (1) | WO2014110685A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021160054A1 (zh) * | 2020-02-11 | 2021-08-19 | 浙江华康药业股份有限公司 | 一种肠内缓释糖醇添加剂及其制备方法和应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
WO2016183319A1 (en) * | 2015-05-13 | 2016-11-17 | University Of Florida Research Foundation, Incorporated | Propionibacterium fruedenreichii as a probiotic for infants |
WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
GB201509023D0 (en) * | 2015-05-27 | 2015-07-08 | Optibiotix Ltd | Compositions and methods of production thereof |
WO2017117142A1 (en) | 2015-12-28 | 2017-07-06 | New York University | Device and method of restoring microbiota of newborns |
EP3850953B1 (en) | 2016-06-10 | 2023-11-01 | N.V. Nutricia | Nutrition to reduce the risk of allergy |
EP3388069B1 (en) | 2017-04-12 | 2019-05-01 | ETH Zurich | Consortia of living bacteria useful for treatment of microbiome dysbiosis |
US20220054560A1 (en) * | 2018-10-15 | 2022-02-24 | Pharmabiome Ag | Consortia of living bacteria useful for treatment of colorectal cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
EP1308506A1 (en) * | 2001-11-06 | 2003-05-07 | Eidgenössische Technische Hochschule Zürich | Mixtures of Propionibacterium jensenii and Lactobacillus sp. with antimicrobial activities for use as a natural preservation system |
EP1374878A1 (en) | 2002-06-20 | 2004-01-02 | N.V. Nutricia | Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract |
WO2004001022A1 (en) | 2002-06-21 | 2003-12-31 | The University Of Newcastle Research Associates (Tunra) Ltd | Probiotic propionibacterium jensenii 702 |
GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
US20100166721A1 (en) | 2006-06-09 | 2010-07-01 | Fabiola Masri | Probotic compositions and uses thereof |
CN102695427B (zh) | 2009-08-18 | 2016-04-13 | 雀巢产品技术援助有限公司 | 包含乳球菌属菌株并且特别是在婴儿和儿童中减少过敏症状的营养组合物 |
EP2449890A1 (en) | 2010-11-05 | 2012-05-09 | Nestec S.A. | Powdered cereal compositions comprising non-replicating probiotic microorganisms |
CN103763940B (zh) | 2010-12-31 | 2015-10-14 | 雅培制药有限公司 | 促进有益微生物群生长的益生菌和人乳寡糖的合益素组合 |
-
2014
- 2014-01-14 US US14/761,336 patent/US20150352162A1/en not_active Abandoned
- 2014-01-14 EP EP14700426.1A patent/EP2945494B1/en active Active
- 2014-01-14 CA CA2897363A patent/CA2897363C/en active Active
- 2014-01-14 ES ES14700426.1T patent/ES2620057T3/es active Active
- 2014-01-14 JP JP2015552957A patent/JP2016505024A/ja active Pending
- 2014-01-14 WO PCT/CH2014/000006 patent/WO2014110685A1/en active Application Filing
- 2014-01-14 CN CN201480005065.3A patent/CN104936464A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021160054A1 (zh) * | 2020-02-11 | 2021-08-19 | 浙江华康药业股份有限公司 | 一种肠内缓释糖醇添加剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
ES2620057T3 (es) | 2017-06-27 |
CA2897363C (en) | 2016-06-21 |
JP2016505024A (ja) | 2016-02-18 |
WO2014110685A1 (en) | 2014-07-24 |
US20150352162A1 (en) | 2015-12-10 |
EP2945494B1 (en) | 2017-03-08 |
EP2945494A1 (en) | 2015-11-25 |
CA2897363A1 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104936464A (zh) | 包含产丙酸活细菌的婴儿食物组合物 | |
US8377430B2 (en) | Infant formula with probiotics | |
CN103582426A (zh) | 寡糖混合物以及包含该混合物的食品,特别是婴儿配方产品 | |
MX2011006701A (es) | Prevencion y tratamiento de diarrea por rotavirus. | |
SG191392A1 (en) | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides | |
TWI639387B (zh) | 用於預防胃腸道受傷及/或促進胃腸道治癒之半乳寡糖 | |
TW201006392A (en) | Nutritional composition containing oligosaccharide mixture | |
JP2016505024A5 (zh) | ||
CN106998775A (zh) | 具有RRR‑α‑生育酚、2’‑岩藻糖基乳糖和益生菌的婴儿配方 | |
US20210113630A1 (en) | Methods for increasing growth of beneficial bacteria in the gastrointestinal tract | |
UA107081C2 (uk) | Профілактика і лікування алергічної діареї | |
MX2013005943A (es) | Uso de composiciones nutricionales que incluyen lactoferrina en apoyo de la resistencia a enfermedades y condiciones. | |
WO2022266058A1 (en) | Methods and compositions for treating gas | |
US11246894B2 (en) | Superfood supplement for dogs and its manufacturing process | |
US11179427B2 (en) | Baby food composition comprising viable propionic acid-producing bacteria | |
TW201822640A (zh) | 包含麥芽三糖之組成物,及使用彼以抑制由脫水方法導致之傷害的方法 | |
JP2003246753A (ja) | 腸内フローラ改善剤及び飲食品 | |
TW202348240A (zh) | 用於減少與個體產生之氣體相關之氣味的方法及組合物 | |
BR112019008752B1 (pt) | Composição sob a forma de pó, que compreende complexos de ferroproteína do leite e bactérias probióticas | |
Patel | A Comparative Study on Animal Colostrums Probiotics as Emerging Neutraleuticles | |
CN116981463A (zh) | 人乳低聚糖 | |
BR112021004949A2 (pt) | composições nutricionais, seu uso na redução do estresse metabólico e método para reduzir o estresse metabólico | |
MX2008010261A (en) | Oligosaccharide mixture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150923 |
|
WD01 | Invention patent application deemed withdrawn after publication |